Insights

Innovative Platform Smart Immune's proprietary ProTcell platform offers advanced T-cell therapies targeting cancer and infectious diseases, presenting opportunities to collaborate on next-generation immuno-oncology treatments and personalized immune solutions.

Funding Momentum With recent €17.5 million in EU funding and $5 million from the Bill & Melinda Gates Foundation, the company is actively expanding its development capabilities, making it a prime target for partnerships and investment in immune therapy innovations.

Clinical Advancement The ongoing Phase I/II clinical trials for SMART101 and other therapies indicate regulatory progress and growing market potential, ideal for stakeholders interested in innovative cancer and infectious disease treatments.

Strategic Leadership Recent appointments of seasoned oncology and technical experts bolster Smart Immune's innovation pipeline, offering opportunities to connect with key decision-makers involved in advancing cell therapy solutions.

Market Positioning Recognition as a leading startup in biotechnology and collaborations with top institutions position Smart Immune as a strategic partner for organizations aiming to expand into cutting-edge immune-modulating therapies.

Similar companies to Smart Immune

Smart Immune Tech Stack

Smart Immune uses 8 technology products and services including Google Hosted Libraries, Axeptio, React, and more. Explore Smart Immune's tech stack below.

  • Google Hosted Libraries
    Content Delivery Network
  • Axeptio
    Cookie Compliance
  • React
    Javascript Frameworks
  • Webflow
    Page Builders
  • PHP
    Programming Languages
  • Lua
    Programming Languages
  • OpenResty
    Web Servers
  • Nginx
    Web Servers

Media & News

Smart Immune's Email Address Formats

Smart Immune uses at least 1 format(s):
Smart Immune Email FormatsExamplePercentage
First.Last@smart-immune.comJohn.Doe@smart-immune.com
49%
FirstLast@smart-immune.comJohnDoe@smart-immune.com
1%
First.Middle@smart-immune.comJohn.Michael@smart-immune.com
1%
First.Last@smart-immune.comJohn.Doe@smart-immune.com
49%

Frequently Asked Questions

What is Smart Immune's official website and social media links?

Minus sign iconPlus sign icon
Smart Immune's official website is smart-immune.com and has social profiles on LinkedInCrunchbase.

What is Smart Immune's SIC code NAICS code?

Minus sign iconPlus sign icon
Smart Immune's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Smart Immune have currently?

Minus sign iconPlus sign icon
As of December 2025, Smart Immune has approximately 29 employees across 2 continents, including EuropeNorth America. Key team members include Ceo And Co Founder: K. R.Chief Scientific Officer: O. N.Chief Business Officer & Chief Finance Officer: J. G.. Explore Smart Immune's employee directory with LeadIQ.

What industry does Smart Immune belong to?

Minus sign iconPlus sign icon
Smart Immune operates in the Biotechnology Research industry.

What technology does Smart Immune use?

Minus sign iconPlus sign icon
Smart Immune's tech stack includes Google Hosted LibrariesAxeptioReactWebflowPHPLuaOpenRestyNginx.

What is Smart Immune's email format?

Minus sign iconPlus sign icon
Smart Immune's email format typically follows the pattern of First.Last@smart-immune.com. Find more Smart Immune email formats with LeadIQ.

How much funding has Smart Immune raised to date?

Minus sign iconPlus sign icon
As of December 2025, Smart Immune has raised $5M in funding. The last funding round occurred on Apr 16, 2023 for $5M.

When was Smart Immune founded?

Minus sign iconPlus sign icon
Smart Immune was founded in 2017.

Smart Immune

Biotechnology ResearchÎle-de-france, France11-50 Employees

Smart Immune is a clinical-stage French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to fully and rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies. The company aims to radically improve outcomes for patients in hematology and immune-oncology. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is in Phase I/II clinical trials in cancer patients with AML and ALL, in SCID in the EU and the US. Smart Immune is also developing therapies using gene-modified T cell progenitors through its ProTcell platform to provide targeted treatments like off-the-shelf CAR T. The Company is headquartered in Paris, France, at Paris Biotech Santé.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
11-50

Section iconFunding & Financials

  • $5M

    Smart Immune has raised a total of $5M of funding over 5 rounds. Their latest funding round was raised on Apr 16, 2023 in the amount of $5M.

  • $1M$10M

    Smart Immune's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $5M

    Smart Immune has raised a total of $5M of funding over 5 rounds. Their latest funding round was raised on Apr 16, 2023 in the amount of $5M.

  • $1M$10M

    Smart Immune's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.